GlassScriptPhysician profile
Mark Leslie Rubin
NPI 1194749341
$1,422.76
in general payments reported to CMS, 2019-2025
14 companies · $42.04 in 2025
The $42.04 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $397 · 2021: $187 · 2022: $46.50 · 2023: $150 · 2024: $13.23 · 2025: $42.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $205.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $327.04 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $252.62 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $182.42 | 2022-2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $140.22 | 2019 | |
| Neos Therapeutics, LP | $110.91 | 2019 | |
| Tris Pharma INC | $105.88 | 2021 | |
| Allergan, INC. | $87.43 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $44.71 | 2019-2020 | |
| Corium, LLC | $42.04 | 2025 | Azstarys |
| Lundbeck LLC | $41.24 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.92 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.13 | 2021-2022 | |
| Adlon Therapeutics L.P. | $17.97 | 2021 | |
| Axsome Therapeutics, INC. | $13.23 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.